Chinese biopharmaceutical company: voluntary announcement - First subject dosed with TQB6411, a type 1 innovative drug for injection.

China Biopharmaceuticals announcement, voluntary announcement - the first subject has been dosed with Type 1 innovative drug TQB6411 for injection. In addition to TQB6411, the Group also has TQB2102 in Phase III clinical trials, LM-302 in Phase III clinical trials, LM-305 in Phase I/II clinical trials, TQB2101 in Phase I clinical trials, and dozens of ADC projects in preclinical development, expected to enter clinical stages in the coming 1-2 years.